Y. Shimada

649 total citations
9 papers, 572 citations indexed

About

Y. Shimada is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Gastroenterology. According to data from OpenAlex, Y. Shimada has authored 9 papers receiving a total of 572 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 4 papers in Gastroenterology. Recurrent topics in Y. Shimada's work include Gastric Cancer Management and Outcomes (6 papers), Gastrointestinal Tumor Research and Treatment (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Y. Shimada is often cited by papers focused on Gastric Cancer Management and Outcomes (6 papers), Gastrointestinal Tumor Research and Treatment (4 papers) and Colorectal Cancer Treatments and Studies (4 papers). Y. Shimada collaborates with scholars based in Japan and United States. Y. Shimada's co-authors include Makoto Yoshino, I Nakao, K Futatsuki, A Wakui, N. Ogawa, Tetsuya Taguchi, Yasushi Sakata, Nami Ogawa, Yuh Sakata and T Taguchi and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cancer Therapeutics and Japanese Journal of Clinical Oncology.

In The Last Decade

Y. Shimada

9 papers receiving 541 citations

Peers

Y. Shimada

ONCOL

MB

PRM

SURGE

GASTR

D. Mignard France

G. Stathopoulos Greece

K Nakano Japan

See‐Chun Phan United States

Annett Maderer Germany

Keiichi Akahoshi Japan

Pamela Dumas United States

Melissa Dinolfo United States

Carlo Barone Italy

Arata Sakai Japan

D. Mignard France

Y. Shimada

289 ×0.7

ONCOL

216 ×0.8

MB

92 ×0.4

PRM

83 ×0.5

SURGE

13 ×0.2

GASTR

Citations per year, relative to Y. Shimada Y. Shimada (= 1×) peers D. Mignard

Countries citing papers authored by Y. Shimada

Since Specialization

Citations

This map shows the geographic impact of Y. Shimada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Shimada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Shimada more than expected).

Fields of papers citing papers by Y. Shimada

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Shimada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Shimada. The network helps show where Y. Shimada may publish in the future.

Co-authorship network of co-authors of Y. Shimada

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Shimada. A scholar is included among the top collaborators of Y. Shimada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Shimada. Y. Shimada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Iwasa, Satoru, Masanori Goto, Hiroshi Yasui, et al.. (2012). Multicenter Feasibility Study of Combination Therapy with Fluorouracil, Leucovorin and Paclitaxel (FLTAX) for Peritoneal Disseminated Gastric Cancer with Massive Ascites or Inadequate Oral Intake. Japanese Journal of Clinical Oncology. 42(9). 787–793. 17 indexed citations

2.

Takiuchi, Hiroya, Haruyuki Fukuda, Y. Shimada, et al.. (2010). Randomized phase II study of best-available 5-fluorouracil (5-FU) versus weekly paclitaxel in gastric cancer (GC) with peritoneal metastasis (PM) refractory to 5-FU-containing regimens (JCOG0407).. Journal of Clinical Oncology. 28(15_suppl). 4052–4052. 14 indexed citations

3.

Yamada, Yasuhide, Hironobu Minami, Nozomu Fuse, et al.. (2009). Abstract A260: A phase 1 study of sorafenib (BAY 43-9006) in combination with S-1 plus cisplatin in patients with advanced gastric cancer. Molecular Cancer Therapeutics. 8(12_Supplement). A260–A260. 3 indexed citations

4.

Matsubara, J, Y. Shimada, Atsuo Takashima, et al.. (2008). A Phase I Study of Bolus 5-Fluorouracil and Leucovorin Combined with Weekly Paclitaxel (FLTAX) as First-line Therapy for Advanced Gastric Cancer. Japanese Journal of Clinical Oncology. 38(8). 540–546. 6 indexed citations

5.

Ura, Takashi, Kei Muro, Y. Shimada, et al.. (2004). Definitive chemoradiotherapy may be standard treatment options in clinical stage I esophageal cancer. Journal of Clinical Oncology. 22(14_suppl). 4017–4017. 2 indexed citations

6.

Yamao, Takekazu, Y. Shimada, Hitoshi Kondo, et al.. (1995). Clinical Trial of Continuous Infusion of 5-Fluorouracil Using an Ambulatory Pump for Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology. 25(2). 46–50. 5 indexed citations

7.

Sakata, Yuh, Y. Shimada, Makoto Yoshino, et al.. (1994). [A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 Study Group on Gastrointestinal Cancer].. PubMed. 21(7). 1039–46. 31 indexed citations

8.

Futatsuki, K, A Wakui, I Nakao, et al.. (1994). [Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].. PubMed. 21(7). 1033–8. 154 indexed citations

9.

Shimada, Y., Makoto Yoshino, A Wakui, et al.. (1993). Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.. Journal of Clinical Oncology. 11(5). 909–913. 340 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact